Connect with us

Media OutReach

Uni-Bio Science Group Limited Announces 2024 Annual Results

Published

8 months ago

on

Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share Strengthening Presence in Osteoporosis, Ophthalmology, and Aesthetic Medical Markets

HONG KONG SAR – EQS Newswire – 27 March 2025 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2024 (the “Period”).

Key Accomplishments in 2024

During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. The Group recorded a 14.1% year-on-year (“YoY”) increase in revenue, reaching approximately HK$553.0 million. With its approval in January 2024 and subsequent launch in March 2024, Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations.

2. Profit for the Year soared by16.8% YoY to approximately HK$82.8 million, marking a historic high. These results reaffirm the Group’s solid market position and its ability to deliver sustainable, high-quality growth as a leading biopharmaceutical company.

3. The board of directors (“Board”) has declared a dividend payment for 2024 of HK$0.277 cents per share, marking the historic first for the Company. This is particularly encouraging, as it represents an important milestone for a research-oriented biopharmaceutical company. The Board is also pleased to announce the approval and adoption of a dividend payout policy of no less than 20% of its net profit for the current year.

4. In January 2024, the China National Medical Products Administration (“NMPA”) officially approved the launch of Bogutai®, marking a major breakthrough for the Group in osteoporosis and orthopedic disease management. Since its market debut in early 2024, Bogutai® has gained remarkable traction, achieving a patient retention rate exceeding 70%.

5. In December 2024, the Group successful launch its self-developed medical aesthetics product, 肌顏態®. The recombinant collagen dressing, developed in collaboration with Chongqing Minji Medical Device Co., Ltd., received Class II medical device approval, reinforcing the Group’s commitment to innovative skin repair solutions.

6. In January 2024, the NMPA officially accepted the marketing application for Diquafosol Sodium eye drops, marking a key milestone in the Group’s ophthalmology drug pipeline. During the Year, the Group has already submitted additional data to the Center for Drug Evaluation (CDE). Diquafosol Sodium is expected to receive the marketing approval in the first half of 2025.

7. During the Year, the Group completed the pharmaceutical research and pre-Bioequivalence studies of Esaconazole sulfoate capsules. The formal Bioequivalence trials has been initiated in 2025 to accelerate the launch process.

8. In May 2024, the Group cooperated with Great Bay Bio (GBB) and Pebble Accelerator, a subsidiary of Tigermed to joint development of innovative weight reduction drugs, aiming to revolutionize the treatment of obesity. Through this collaboration, we seek to establish a comprehensive ecological industry chain, spanning from target discovery to antibody generation, druggability verification, process development, clinical pipeline, and ultimately, commercialization.

Annual Results

In 2024, the Group recorded a revenue of approximately HK$553.0 million, representing an increase of 14.1% YoY. The increase in revenue was mainly attributable to the favorable sales performance of the Group’s newly launched product Bogutai®. The Group’s newly launched product Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations. Pinup® recorded a decrease of 2.9% in revenue from approximately HK$247.4 million to approximately HK$240.3 million for the Year. During the Year, the Group was re-selected for the centralized procurement, with a validity period of two years. However, the Group adopted a more selective approach to supplying hospitals in response to certain local policy adjustments. During the Year, revenue generated from GeneTime® was approximately HK$197.9 million, representing an increase of 6.7% YoY. The increase was attributed to the expansion of the Group’s hospital network and additional sales channels beyond hospitals, such as pharmacies and e-commerce platforms. GeneSoft® recorded an increase in revenue from approximately HK$41.3 million to approximately HK$42.5 million, representing an increase of 2.9% YoY. Revenue from Boshutai® declined from approximately HK$10.4 million to approximately HK$9.4 million, representing a decrease of 10.2%. During the Year, Boshutai® was successfully included in the centralized procurement by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years, which secured the Group with new in-hospital orders.

Gross profit was approximately HK$461.1 million, representing an increase of 17.4% as compared with approximately HK$392.8 million in 2023, and gross profit margin increased by 2.4 percentage points YoY to 83.4%. The Group has optimized its supply chain to enhance raw material procurement competitiveness, improve scaling efficiency, and reduce procurement and production costs, achieving greater economies of scale. Thanks to the Group’s diligent internal control, general and administrative expenses accounted for merely 9.2% of revenue in 2024 as compared with 9.8% in 2023. The selling and distribution expenses for the Year also decreased to 47.3% of revenue from 49.8% in 2023, mainly due to the marketing expenses decreased. The R&D expenses increased by47% YoY to approximately HK$52.3 million, aligning with the Group’s multi-pipeline research progress.
The Group achieved another year of record-breaking profit of approximately HK$82.8 million for the Year, marking an impressive increase of 16.8% YoY. This remarkable achievement was fueled by the successfully launch of the new product Bogutai®, along with the consistent demand for other marketed drugs, stringent cost management, and ongoing supply chain enhancements. This sustained profitability strengthened the Group’s foundation for long-term success in the years ahead.

Prospects

Recent advancements in biotechnology, coupled with strong government support, position China’s pharmaceutical landscape for substantial growth, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, according to the IMARC Group. This expansion is driven by technological innovations and a growing elderly population increasingly susceptible to chronic conditions such as diabetes, which boosts pharmaceutical demand. Concurrently, the aesthetic medical sector is emerging as a significant market force, with forecasts indicating a CAGR of 10% to 15% from 2024 to 2027, primarily fueled by rising beauty standards and increased spending among individuals with moderate to high incomes. With the two industries being the Group’s core R&D focuses going forward, it showcases a great potential for the Group to rapidly grow and capture the market shares.

Mr. Kingsley Leung, Chairman of Uni-Bio Science commented, “I am proud to announce that we have reached significant milestones this year, both financially and operationally. As our efforts begin to bear fruit, I am deeply grateful for the unwavering, long-term support of our shareholders. In recognition of this, I am delighted to share two landmark decisions: the declaration of our inaugural dividend and the establishment of a forward-looking dividend payout policy of no less than 20% of its net profit for the current year. These actions reaffirm our steadfast commitment to delivering on our objectives while creating and sustaining value for our shareholders.

Looking forward, we remain steadfast in our commitment to innovation and seizing opportunities within both the pharmaceutical and aesthetic medical sectors. Our vision has consistently focused on diversifying our product offerings while leveraging our strengths in endocrinology, ophthalmology, and dermatology. We are delighted to announce the successful launch of Bogutai® Following this milestone, we will continue to develop best-in-class products, including a PTH microneedle formulation that is less invasive and offers higher bioavailability, as well as a novel antibody drug for weight loss. Significant advancements have also been made in our series of EGF products. Preparations for pilot plant testing of the EGF hydrogel are underway, and Diquafosol Sodium Eye Drop slated for launch in the second quarter of 2025. Additionally, The formal Bioequivalence trials for Esaconazole sulfoate capsules has been initiated in 2025 to accelerate the launch process.

In the aesthetic medical segment, we are excited about the launch of肌顏態® in late December 2024. Building on this momentum, we will accelerate the introduction of other new product lines in 2025 based on Skbrella™ FN. Additionally, we plan to introduce collagen and beauty peptides as advanced skincare raw materials this year. By leveraging our expertise in GeneTime® and 肌顏態®, we aim to create a comprehensive skincare solution for emergency skin repair and stabilization. To foster our product innovation, we are utilizing two new key technology platforms: advanced synthetic biology platform and hydrogel technology. These platforms are expected to drive our product expansion.

To enhance our reach and support product launches, we are expanding our sales channels beyond traditional public and private hospital networks to include pharmacies, online platforms, and aesthetic medical institutions. We are also exploring international markets to bolster our global presence. By adopting a diversified distribution strategy, the Group aims to secure future sales growth while reducing its dependence on regional markets and traditional channels. In support of our company’s growth, the infrastructure for our new factory in Dongguan was fully completed in 2024, marking a significant milestone in our expansion plans. A state-of-the-art BFS packaging line has also been featured, which we believe will enable the Group to command a premium in the market. With these strategic focuses and our commitment to rapid advancement, the Group is well-positioned to solidify its leadership in these dynamic industries and achieve lasting success in the years ahead.”

Hashtag: #Uni-BioScience

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.

Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.

For further information, please contact:

Related Topics:
Advertisement

Media OutReach

SIM and the True Worth of Education: Beyond Tuition Fees

Published

4 hours ago

on

07/12/2025

By

SINGAPORE – Media OutReach Newswire – 7 December 2025 – As Singaporean families plan for higher education, tuition costs often dominate the conversation. However, the more critical consideration lies in understanding the relationship between cost and value. This article provides an in-depth understanding of the financial implications of pursuing studies at local public universities, private institutions such as SIM, and overseas universities, while highlighting SIM’s distinctive proposition that extends beyond competitive pricing.

Local Public Universities: Affordable and Prestigious

Singapore’s autonomous universities remain among the most cost-effective options for Singapore citizens, thanks to the Ministry of Education’s Tuition Grant. For example, undergraduate programs at NUS and NTU cost around S$8,250 per year for Singaporeans, while SMU averages S$11,500 annually. Other institutions such as SUTD, SUSS and SIT fall within similar ranges, typically between S$8,000 and S$13,500 per year. Over a three- to four-year degree, this translates to roughly S$25,000 to $54,000 in tuition fees.

The autonomous universities offer strong reputations and excellent graduate outcomes, but entry to some programme is highly competitive, and program flexibility may be limited compared to private or overseas options.

Overseas Universities: Prestige Comes at a Price

For families considering an overseas education, costs escalate dramatically. Tuition at U.S. private universities averages US$50,000 to US$60,000 per year (about S$70,000 to S$84,000), with living expenses adding another US$10,000 to US$15,000 annually. In the UK, fees range from £10,000 to £38,000 per year (approximately S$17,000 to $65,000), while Canada and Australia typically charge S$14,000 to $28,000 for tuition alone. Factoring in accommodation, travel, and insurance, a four-year overseas degree can easily exceed S$150,000.

While these programs offer prestige and cultural immersion, they also involve significant financial, visa, and lifestyle considerations.

SIM Global Education: International Degrees at Local Cost

SIM offers a compelling alternative for students seeking global credentials without the high cost of studying abroad. Through partnerships with leading universities from the UK, Australia, the U.S., Canada, and Europe, SIM delivers more than 140 programs in Singapore, allowing students to earn internationally recognized degrees, essentially the same degree if you studied overseas, but locally at SIM. Tuition fees vary by program, for example, a University of London BSc ranges from S$26,685 to S$42,835, a University of Birmingham top-up degree costs S$42,000 to S$57,100, and a degree from the University at Buffalo falls between S$41,700 and S$74,600 for Singaporeans.

Beyond competitive pricing, SIM emphasizes value. Degrees are awarded by partner universities and aligned with global academic standards. The institution holds EduTrust Star certification and ISO accreditation, ensuring the best quality assurance. Students benefit from bond-free scholarships and bursaries, as well as Career Connect services that provide internships, mentoring, and employer networking. Graduate outcomes are strong, with nearly 80% of SIM graduates securing employment within six months of graduation.

Why Value Matters as Much as Cost

Choosing a degree isn’t just about tuition fees, it’s about the total investment, which includes living costs, global recognition, and career outcomes. Local autonomous universities such as NUS, NTU, and SMU remain highly attractive for their subsidized fees and strong reputations, making them one of the most cost-effective options for Singaporeans. However, entry is competitive, and program flexibility may be limited.

On the other end of the spectrum, overseas universities offer prestige and cultural immersion but often come with six-figure costs and additional living expenses. This is where SIM provides a strategic middle ground, delivering internationally recognized degrees from leading global universities at local cost. Students gain access to global curricula, industry-ready skills, and career networks without the financial burden of relocating overseas. For families seeking international exposure at sustainable costs, SIM combines affordability with the value of global education

References:

  1. NUS Fees for Undergraduate Programmes – https://www.nus.edu.sg/registrar/docs/info/administrative-policies-procedures/ugtuitioncurrent.pdf
  2. NTU Fees for Undergraduate Programmes – https://www.ntu.edu.sg/docs/default-source/onestop@sac/2025/tuition-fees-ft-ay2025_12mar25.pdf?sfvrsn=b8c5474_1
  3. SMU Fees for Undergraduate Programmes – https://admissions.smu.edu.sg/financial-matters/tuition-fees-grant
  4. SUTD Fees for Undergraduate Programmes – https://www.sutd.edu.sg/admissions/undergraduate/education-expenses/fees/tuition-fees/
  5. SUSS Fees for Undergraduate Programmes – https://www.suss.edu.sg/admissions/financial-matters/tuition-fee-subsidy/full-time-undergraduate
  6. SIT Fees from Undergraduate Programmes – https://www.suss.edu.sg/admissions/financial-matters/tuition-fee-subsidy/full-time-undergraduate
  7. Comparison of Tuition Fees in US, UK, Canada and Australia – https://uninist.com/blog/financial-planning/comparison-of-tuition-fees-guide
  8. How much does college cost in 2025 – https://research.com/universities-colleges/how-much-does-college-cost
  9. Price of attending undergraduate institutions – https://nces.ed.gov/programs/coe/indicator/cua
  10. University of London Bachelor Degree – https://www.sim.edu.sg/degrees-diplomas/programmes/programme-listing?academic=2%7C&programmetype=1%7C3&university=1%7C
  11. University of Brimingham Bachelor Degree – https://www.sim.edu.sg/degrees-diplomas/programmes/programme-listing?academic=2%7C&programmetype=1%7C3&university=10%7C

Hashtag: #SIMGlobalEducation #SIMGE #GlobalEducation #InternationalDegree #CareerReady #FutureSkills

The issuer is solely responsible for the content of this announcement.

About SIM Global Education

SIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor’s and master’s degree programmes with some of the world’s most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE’s cohort is made up of 16,000 full- and part-time students and adult learners, of which approximately 36% are international students hailing from over 50 countries.

SIM GE’s holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world.

For more information on SIM Global Education, visit sim.edu.sg

Continue Reading

Media OutReach

A-Level vs Polytechnic: Understanding different pathways offer competitive edge at SIM

Published

21 hours ago

on

06/12/2025

By

SINGAPORE – Media OutReach Newswire – 6 December 2025 – Singapore’s education system offers two popular tertiary pathways after post-secondary, A-Levels through Junior Colleges and Polytechnic diplomas. Both leading to higher education but differ in focus. A-Levels are academically rigorous and theory-driven, preparing students for university through subject-based learning over two years at junior colleges or three years at Millennia Institute.

Conversely, Polytechnic programmes emphasize applied learning, incorporating projects and industry attachments, and culminate in a diploma after three years. Understanding how these distinct approaches translate into admission considerations at SIM, one of Singapore’s leading private education institutions, is essential.

For students and parents, evaluating these options is critical to determining which pathway offers the greatest advantage in today’s competitive education landscape.

Applying with A-Levels

For students who have completed A-Levels, SIM requires applicants to meet the academic and English language criteria specified for each degree programme. According to SIM’s admissions process, candidates must submit their GCE A-Level certificates and transcripts along with other supporting documents. Entry is subject to programme-specific requirements set by SIM and its universities partner from Australia, Canada, Europe, the United Kingdom, and the United States. This pathway allows applicants to begin their degree studies immediately after junior college, provided they meet the specific entry requirements for their chosen programme.

Applying with a Polytechnic Diploma

Polytechnic graduates may be eligible for advanced standing and credit exemptions when applying to SIM’s degree programmes. The amount of exemption depends on the relevance of the diploma and the chosen degree. For example, IT-related diplomas from local polytechnics can receive up to two years of credit exemptions for certain programmes, such as those offered by the University of Wollongong, provided the applicant meets GPA requirements (typically 2.0 or above). Other diplomas may receive partial exemptions on a case-by-case basis. These exemptions reduce both time and cost, making SIM an attractive option for Polytechnic graduates who want to build on their applied learning experience.

Why It Matters

According to the Ministry of Education (MOE) statistics in 2021, roughly one in three Polytechnic graduates progress to local autonomous universities, compared to about four in five A‑Level and International Baccalaureate graduates. This gap underscores the importance of additional pathways such as SIM, which enable Polytechnic graduates to earn globally recognised degrees and expand their career prospects.

Student Stories: Two Potential Paths to Success at SIM

At SIM, students have the flexibility to shape their academic journey based on their background and career goals. For some, it’s about gaining a head start; for others, it’s about leveraging credit exemptions to fast-track progress. Ashley Ong and Violet Weng exemplify these two pathways, each leading to success in its own way.

Ashley Ong, an A-Level graduate, chose to begin her degree journey with the University at Buffalo Bachelor of Science in Business Administration. She embraced every opportunity SIM offered such as internships, hackathons, and networking events, building practical skills and global perspectives that prepared her for a competitive business world.

Meanwhile, Violet Weng, a Singapore Polytechnic graduate, opted for a different approach. While pursuing her RMIT Bachelor of Business (Economics and Finance), Violet leveraged SIM’s credit exemptions to shorten her study duration and reduce costs, all while working full-time. This flexibility allowed her to balance work and study, accelerate graduation, and advance her career without compromise.

Both stories highlight SIM’s commitment to offering customized pathways for students whether you’re starting fresh or building on prior learning.

Conclusion

Whether you come from an academic route like A-Levels or an applied learning path through Polytechnic, the journey to a degree can look very different. A-Level graduates often enjoy a head start with direct entry, while Polytechnic graduates benefit from credit exemptions that recognize their practical skills. Both pathways reflect Singapore’s evolving education landscape where flexibility and global opportunities matter more than ever.

References:

  1. MOE Post-Secondary – https://www.moe.gov.sg/post-secondary/
  2. SIM Application Process – https://www.sim.edu.sg/degrees-diplomas/admissions/application-process
  3. SIM-UOW Credit Exemption Table – https://www.sim.edu.sg/getmedia/9c0ad90d-5910-4d47-b044-f815188a4b16/sim002856.pdf
  4. MOE Education Statistics Digest – https://www.moe.gov.sg/about-us/publications/education-statistics-digest
  5. Polytechnic graduates progression and subsidies for PEIs – https://www.moe.gov.sg/news/parliamentary-replies/20210510-polytechnic-graduates-progression-and-subsidies-for-peis
  6. askST: How many uni places are there for Singaporeans? Is there a quota for poly grads? – https://www.straitstimes.com/singapore/how-many-uni-places-for-locals-any-quota-for-poly-grads
  7. How 6 internships, 4 hackathons, and CCAs paved the way for Ashley – https://www.sim.edu.sg/articles-inspirations/how-6-internships-4-hackathons-and-ccas-paved-the-way-for-ashley
  8. How this graduate pivoted her career by pursuing a degree while working full time – https://www.sim.edu.sg/articles-inspirations/how-this-graduate-pivoted-her-career-by-pursuing-a-degree-while-working-full-time

Hashtag: #SIMGlobalEducation #SIMGE

The issuer is solely responsible for the content of this announcement.

About SIM Global Education

SIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor’s and master’s degree programmes with some of the world’s most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE’s cohort is made up of 16,000 full- and part-time students and adult learners, of which approximately 36% are international students hailing from over 50 countries.

SIM GE’s holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world.

For more information on SIM Global Education, visit sim.edu.sg

Continue Reading

Media OutReach

K. Wah Group Donates Additional HK$12.07 Million for Tai Po Recovery

Published

1 day ago

on

06/12/2025

By

Chairman Mr. Francis Lui Urges Public to Turn Compassion into Action and Vote 7 December

HONG KONG SAR – Wechat: 嘉华集团 K. Wah Group

The issuer is solely responsible for the content of this announcement.

About K. Wah Group

K. Wah Group was founded in 1955 by Dr. Lui Che Woo and has since grown into a diversified multinational corporation. Its core businesses span property development and investment, integrated resort and entertainment, hospitality, and construction materials.

The Group has a strong presence in Mainland China, Hong Kong, Macau, Southeast Asia, and key international markets. Its major subsidiaries include two Hong Kong-listed flagships: K. Wah International Holdings Limited (HKEX: 00173), focused on premium property development and investment; and Galaxy Entertainment Group Limited (HKEX: 00027), a constituent of the Hang Seng Index and a leading gaming and entertainment operator in Macau. Other key members of the Group include Stanford Hotels International and K. Wah Construction Materials Limited. Today, K. Wah Group comprises over 200 subsidiaries worldwide.

Website：

Continue Reading

Trending